Higher SARS-CoV-2 Spike Binding Antibody Levels and Neutralization Capacity 6 Months after Heterologous Vaccination with AZD1222 and BNT162b2

Within a year after the emergence of SARS-CoV-2, several vaccines had been developed, clinically evaluated, proven to be efficacious in preventing symptomatic disease, and licensed for global use. The remaining questions about the vaccines concern the duration of protection offered by vaccination an...

Descrición completa

Detalles Bibliográficos

Principais autores:	Brigitte Müller-Hilke, Franz Mai, Michael Müller, Johann Volzke, Emil C. Reisinger
Formato:	Artigo
Idioma:	Inglês
Publicado:	MDPI AG 2022-02-01
Series:	Vaccines
Assuntos:	SARS-CoV-2 COVID-19 heterologous prime-boost vaccination variant of concern humoral and cellular immune response
Acceso en liña:	https://www.mdpi.com/2076-393X/10/2/322
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!